glp-1 agonists cardiovascular diseases Glucagon-like peptide 1 receptor agonists: benefits and mechanisms of action The Unstoppable Rise of GLP-1

no GLP-1 RA is on this list

Standard of Care) study for alogliptin (58, 62), the Savor-TIMI-53 study (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes MellitusThrombolysis in Myocardial Infarction 53) for saxagliptin (60, 63), the TECOS study (Trial Evaluating Cardiovascular Outcomes With Sitagliptin) for sitagliptin (59, 64) and the CARMELINA study (Cardiovascular safety and Clinical Outcome with Linagliptin) for linagliptin (61, 65)

Zu den gngigen Medikamenten gehren: Semaglutid (Ozempic, Wegovy) Liraglutid (Saxenda) Dulaglutid (Trulicity) Exenatid (Byetta) Tirzepatid (Mounjaro) dualer Agonist, wirkt an GLP1 und GIPRezeptoren Die meisten GLP-1-Agonisten werden tglich oder wchentlich in Form einer Abnehmspritze als Injektion unter die Haut verabreicht

Stekovic, S

Studies have shown positive results indicating that GLP-1 or its analog can reduce hepatic gluconeogenesis and lipogenesis, suggesting that GLP-1 can be used in the treatment of NASH 29,30,31

23% on placebo) and 63% experienced a BMI reduction of 10% (vs